Gujarat Themis Biosyn Ltd vs Panacea Biotec Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 386.65 as of 11 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Panacea Biotec Ltd changed from 0.8 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Panacea Biotec Ltd changed from ₹ 1086 crore on March 2021 to ₹ 2699 crore on March 2025 . This represents a CAGR of 19.96% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Panacea Biotec Ltd for the Dec '25 is ₹ 170.24 crore as compare to the Sep '25 revenue of ₹ 150.23 crore. This represent the growth of 13.32% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Panacea Biotec Ltd for the Dec '25 is ₹ 16.79 crore as compare to the Sep '25 ebitda of ₹ -8.69 crore. This represent the decline of -293% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Panacea Biotec Ltd changed from ₹ -15.88 crore to ₹ 3.89 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Panacea Biotec Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Panacea Biotec Ltd

India's leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Limited.
The name of the Company was changed to the present 'Panacea Biotec Limited' in 1993. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Panacea Biotec Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Panacea Biotec Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,213 Cr while Market cap of Panacea Biotec Ltd is 2,335 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Panacea Biotec Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Panacea Biotec Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Panacea Biotec Ltd?

As of May 12, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹386.65. On the other hand, Panacea Biotec Ltd stock price is INR ₹381.3.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Panacea Biotec Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Panacea Biotec Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.